Literature DB >> 20871471

Why preoperative acuity predicts postoperative acuity in wavefront-guided LASIK.

Michelle T Aaron1, Raymond A Applegate, Jason Porter, Larry N Thibos, Steve C Schallhorn, Tyson J Brunstetter, David J Tanzer.   

Abstract

PURPOSE: To critically evaluate the following clinical wisdom regarding custom (wavefront-guided) laser in situ keratomileusis (LASIK) that subjects with better-than-average best-corrected visual acuity (BCVA) before surgery have a greater risk of losing BCVA postoperatively than do subjects with worse-than-average BCVA before surgery.
METHODS: High contrast BCVA was measured once before and 3 months after custom LASIK in one eye of 79 subjects. Preoperative spherical equivalent refractive error ranged between -1.00 and -10.38 D. The sample was divided into one of two subsamples: eyes that had better-than-average preoperative BCVA (<-0.11 logMAR) and eyes that had average or worse-than-average preoperative BCVA (≥-0.11 logMAR). Controls were implemented for retinal magnification and for the statistical phenomenon of regression to the mean of the preoperative acuity measurement.
RESULTS: On average, for the entire sample, moving the correction from the spectacle plane to the corneal plane increased letter acuity 4.7% (1 letter, 0.02 logMAR). For each subsample, the percentage regression to the mean was 57.24%. After correcting for magnification effects and regression to the mean, eyes with better-than-average preoperative acuity had a small but significant gain in acuity (∼1 letter, p = 0.040) that was nearly identical to the gain for eyes with worse-than-average preoperative acuity (∼1.5 letters, p = 0.002).
CONCLUSIONS: Custom LASIK produced a statistically significant gain in visual acuity after correction for magnification effects. Dividing the sample into two subsamples based on preoperative acuity confirmed the common clinical observation that eyes with better-than-average acuity tend to remain the same or lose acuity, whereas eyes with worse-than-average acuity tend to gain acuity. However, when only one acuity measurement is taken at a single time point and the sample is subsampled nonrandomly, this clinical observation is due to a statistical artifact (regression to the mean) and is not attributable to the surgery.

Entities:  

Mesh:

Year:  2010        PMID: 20871471      PMCID: PMC2981088          DOI: 10.1097/OPX.0b013e3181f6fb49

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  8 in total

Review 1.  Making sense out of wavefront sensing.

Authors:  Jay S Pepose; Raymond A Applegate
Journal:  Am J Ophthalmol       Date:  2005-02       Impact factor: 5.258

2.  The effect of regression to the mean in epidemiologic and clinical studies.

Authors:  C E Davis
Journal:  Am J Epidemiol       Date:  1976-11       Impact factor: 4.897

3.  Visual acuity changes throughout adulthood in normal, healthy eyes: seeing beyond 6/6.

Authors:  D B Elliott; K C Yang; D Whitaker
Journal:  Optom Vis Sci       Date:  1995-03       Impact factor: 1.973

Review 4.  Magnification and visual acuity in refractive surgery.

Authors:  R A Applegate; H C Howland
Journal:  Arch Ophthalmol       Date:  1993-10

5.  Regression towards the mean.

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1994-06-04

Review 6.  Some examples of regression towards the mean.

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1994-09-24

7.  Visual experience and patient satisfaction with wavefront-guided laser in situ keratomileusis.

Authors:  Kuang-mon Ashley Tuan
Journal:  J Cataract Refract Surg       Date:  2006-04       Impact factor: 3.351

8.  Optical factors in increased best spectacle-corrected visual acuity after LASIK.

Authors:  Uzeyir Erdem; Orkun Muftuoglu
Journal:  J Refract Surg       Date:  2006-11       Impact factor: 3.573

  8 in total
  1 in total

1.  Assessing regression to the mean effects in health care initiatives.

Authors:  Ariel Linden
Journal:  BMC Med Res Methodol       Date:  2013-09-28       Impact factor: 4.615

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.